Be Aware Canagliflozin Might Increase Amputation Risk in Diabetes Patients

Reports of amputation with canagliflozin (Invokana, Invokamet) will raise more questions about the safety of SGLT2 inhibitors.

This is the latest in a growing list of "flozin" concerns...ketoacidosis, urinary tract infections, yeast infections, etc.

Amputations, mainly of the toe or mid-foot, are seen in about 6 in 1,000 patients taking canagliflozin per year...compared to about 3 in 1,000 patients per year on other diabetes meds.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote